E-MAIL UPDATES

Click here to join

Investors & Media

What's new.

Press releases

Press releases.

Immutep to Participate in Two Upcoming Investor Conferences

September 26th 2022
press releases

Immutep Receives A$2.7 million R&D Tax Incentive from French Government

September 23rd 2022
press releases

Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

September 14th 2022
press releases
more

Investor updates

Investor updates.

Investor Update ASCO 2022 Special Edition June 2022

June 17th 2022
investor updates

Investor Update - February 2022

February 18th 2022
investor updates

Investor Update - April 2021

April 14th 2021
investor updates
more

Analyst reports

Analyst reports.

goetzpartners securities Research - Immutep Limited (IMM-AU): Boosting checkpoint utility in lung and other solid cancers

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

September 15th 2022
analyst reports

CLSA Equity Research - Immutep : On to the main acts (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

September 5th 2022
analyst reports

CLSA Equity Research - Immutep FY22 Result: Cash runway to early-CY24; may prioritise 1L NSCLC trial (which is in combo with Keytruda) (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

August 31st 2022
analyst reports
more